Full-Time

Lead Consultant

Platform Engineering, Cribl & Sentinel

Posted on 9/8/2026

Deadline 9/16/26
AstraZeneca

AstraZeneca

10,001+ employees

Global pharmaceutical company developing prescription medicines

No salary listed

Chennai, Tamil Nadu, India

In Person

Bachelor's

Category
Cybersecurity (2)
,
Required Skills
PowerShell
Microsoft Azure
Python
Data Visualization
Machine Learning
Role-based Access Control

Get referred to AstraZeneca

See people who can refer or advise you

Requirements
  • Typically 7+ years of experience in cybersecurity technologies and processes, with substantial hands-on experience engineering security tools, administering platforms, and maintaining systems in large enterprise environments.
  • Practical experience operating and supporting enterprise platforms for monitoring, telemetry management, investigation, detection, response, and protection.
  • Hands-on expertise with Cribl, including telemetry routing, stream or pipeline management, parsing, transformation, enrichment, filtering, masking, troubleshooting, performance tuning, and operational administration in enterprise environments.
  • Hands-on experience with Microsoft Sentinel, including data connector administration, telemetry onboarding, Security Information and Event Management configuration, Kusto Query Language queries and issue resolution, analytics enablement, dashboards or workbooks, automation support, retention settings, access controls, and operational support of a cloud-native Security Information and Event Management platform.
  • Experience with platform configuration, upgrades, issue resolution, telemetry onboarding, connector or agent management, service reliability, and operational optimization at scale.
  • Experience across multiple security technologies, ideally including Security Information and Event Management, telemetry pipelines, endpoint security, cloud security, identity tooling, and network security.
  • Expertise developing, implementing, and optimizing cybersecurity strategies, frameworks, standards, and operating models within the security tooling domain.
  • Experience identifying and assessing security risks across enterprise technologies, with understanding of telemetry analysis, operational issue investigation, threat actors, attack vectors, and detection and response activities across tooling platforms.
  • Experience in regulated and compliance-aware environments, including governance controls, policies, standards, procedures, audit requirements, and security data-handling expectations.
  • Experience collaborating with business partners and managing relationships and communications with third-party suppliers, vendors, and service partners in complex, global, matrixed environments.
  • Ability to lead through change and adapt to evolving hybrid, cloud-native, and vendor-based security ecosystems.
  • Expertise in security tooling and ability to solve key technical challenges.
  • Comfort applying, evaluating, or supporting artificial intelligence and machine learning concepts in security tooling use cases.
  • Experience using scripting and automation technologies such as PowerShell or Python to improve operational efficiency, scalability, service quality, and platform supportability.
  • Bachelor's degree or equivalent experience in information security, computer science, engineering, or a related field.
Responsibilities
  • Own service performance, resilience, and stability for security tooling across regions and drive consistent delivery according to organizational standards and frameworks.
  • Configure, operate, and continually improve core security platforms to meet service-level agreements, ensure supportability, and scale with demand.
  • Engineer and coordinate telemetry routing, decoding, modification, augmentation, and tuning with Cribl to deliver efficient, governed, cost-effective data pipelines to downstream systems.
  • Manage Microsoft Sentinel connectors, onboarding, normalization, Kusto Query Language issue resolution and optimization, data analysis, reporting interfaces, automation, retention, role-based access control, and platform health.
  • Define and refine service models, tooling criteria, and operational procedures to improve maturity and predictable delivery.
  • Build and sustain integrations across Security Information and Event Management, endpoint, identity, cloud, network, storage, and Information Technology Service Management systems.
  • Enable and tune analytics rules, alerts, dashboards, and operational use cases to improve platform efficiency and response precision.
  • Integrate and optimize endpoint and protection technologies to ensure resilient telemetry flow and policy supportability.
  • Lead incident, problem, change, release, and service reviews and promote ongoing operational improvement.
  • Align services to policies, standards, audits, and regulatory expectations; assess risks and close control gaps proactively.
  • Identify opportunities, implement innovations, and deliver change with training and adoption plans.
  • Lead complex onboarding, integrations, migrations, upgrades, and modernization initiatives to quality, security, and timeline targets.
  • Communicate performance and risk to technical and senior collaborators and build priorities and investment for enterprise outcomes.
  • Guide internal teams and external partners to deliver quality, supportability, and measurable improvements.
  • Use vendor and industry relationships to introduce practices and solutions that advance the security tooling environment.
  • Act as a specialist problem solver, set standards, share knowledge, and mentor engineers and analysts.
  • Apply and evaluate artificial intelligence and machine learning for automation, anomaly detection, enrichment, investigation support, workflow optimization, and content tuning with appropriate governance.
Desired Qualifications
  • Experience with Microsoft Defender for Endpoint, particularly integrated with Microsoft Sentinel, endpoint telemetry pipelines, or broader security operations workflows.
  • Experience with the wider Microsoft security ecosystem across identity, endpoint, cloud, and telemetry services.
  • Experience supporting Security Information and Event Management migration, telemetry pipeline modernization, or large-scale security tooling transformation initiatives.
  • Knowledge of the National Institute of Standards and Technology Cybersecurity Framework, ISO 27001, Center for Internet Security Controls, and regulated environments such as SOX or GxP.
  • Relevant security or platform certifications aligned to Cribl, Microsoft Sentinel, cloud security, or the broader tooling domain.
  • Experience working in large, supervised, global organizations and collaborating across multicultural and geographically dispersed teams.

AstraZeneca develops and markets prescription medicines and vaccines for global health, focusing on oncology, cardiovascular/metabolic, respiratory, and infectious diseases. Its products work by targeting specific biological pathways or cells to treat diseases or prevent infections, using small-molecule drugs, biologics, and vaccines. The company differentiates itself through its dual heritage from Sweden and the UK, a broad pipeline, and strong R&D with collaborations to move from discovery to patient access across multiple therapeutic areas. Its goal is to improve people’s health by discovering, developing, and delivering medicines and vaccines worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Cambridge, United Kingdom

Founded

1913

Get referred to AstraZeneca

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • EU approved Enhertu plus pertuzumab on September 1, 2026, unlocking another breast-cancer line.
  • Amgen and AstraZeneca’s DeLLphi-305 met overall-survival goals for Imdelltra plus Imfinzi.
  • AstraZeneca committed £300 million in April 2026 to Cambridge and Macclesfield expansion.

What critics are saying

  • Reuters on August 17, 2026 said AstraZeneca ended volrustomig’s lung-cancer trial after futility.
  • China indicted Leon Wang and AstraZeneca’s local unit in February 2026; trial risk persists.
  • Forxiga faces patent losses in Poland, Portugal, Australia, and 2027 generic-launch pressure.

What makes AstraZeneca unique

  • AstraZeneca’s 2026 cancer franchise spans Imfinzi, Tagrisso, Enhertu, and Datroway globally.
  • Its UK-Sweden operating base supports Cambridge and Macclesfield R&D plus manufacturing.
  • Daiichi Sankyo and Amgen partnerships broaden AstraZeneca’s reach without full internal capital burden.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Paid Holidays

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

2%

2 year growth

4%
Yahoo Finance
Sep 11th, 2026
Cramer avoids AstraZeneca as trial failures and regulatory pressures overshadow $15.4B revenue

Jim Cramer stated on Mad Money that he is not investing in AstraZeneca, comparing it to Novartis and expressing concerns about missed clinical trials. He believes the company's COPD programme is insufficient to change his view. AstraZeneca reported second-quarter revenue of $15.38 billion, up 6.4% year-on-year, with adjusted earnings per share of $2.63 beating estimates. Growth was driven by oncology and rare disease treatments, offsetting generic competition. However, the company faces significant challenges. The drug anselamimab failed its primary endpoint in a Phase III trial, whilst datopotamab deruxtecan delivered mixed results in lung cancer studies. AstraZeneca's blockbuster drug Farxiga will face a 68% Medicare price reduction from 2026 under the Inflation Reduction Act. The company also contends with regulatory investigations in China involving senior executives.

Yahoo Finance
Sep 11th, 2026
Amgen and AstraZeneca lung cancer drug combo meets survival goal in phase III study

Amgen and AstraZeneca announced positive results from the phase III DeLLphi-305 study evaluating Amgen's Imdelltra (tarlatamab) combined with AstraZeneca's Imfinzi (durvalumab) as first-line maintenance treatment for extensive-stage small-cell lung cancer (ES-SCLC). The study met its primary endpoint of overall survival and key secondary endpoint of progression-free survival, with no new safety concerns identified. ES-SCLC affects approximately 195,000 people globally. If approved, the combination would compete with Jazz Pharmaceuticals' Zepzelca plus Roche's Tecentriq, which received FDA approval in October 2025. Imdelltra, approved in 2024 for ES-SCLC progression after platinum-based chemotherapy, generated $546 million in global sales during the first half of 2026, up from $215 million in the prior-year period.

The Telegraph
Sep 9th, 2026
AstraZeneca buys biotech company for £120m

Drug giant AstraZeneca has agreed to buy KuDOS Pharmaceuticals, a UK biotech company, for $210mn (£120m).

Yahoo Finance
Sep 8th, 2026
AstraZeneca shares slip 0.7% despite Imfinzi trial success in lung cancer treatment

AstraZeneca shares declined approximately 0.7% to $161.51 despite positive late-stage trial results for Imfinzi in treating extensive-stage small-cell lung cancer. The 563-patient DeLLphi-305 trial met its primary overall-survival goal when Imfinzi was combined with Amgen's Imdelltra, also improving progression-free survival and response rates with no new safety concerns. However, the companies have not released numerical survival data, leaving investors unable to assess the treatment's competitive strength. Imfinzi generated $6.06 billion in 2025, whilst oncology represented approximately 46% of AstraZeneca's $30.7 billion first-half 2026 revenue. The shares now trade 10.72% below their $180.91 valuation estimate. AstraZeneca must share economics with Amgen and demonstrate that the treatment's added complexity can convert into meaningful sales growth.

Executive Bulletin
Sep 7th, 2026
First Oncology Summit in Lebanon hosted by AstraZeneca brings together regional experts to advance the Future of Cancer Care.

First Oncology Summit in Lebanon hosted by AstraZeneca brings together regional experts to advance the Future of Cancer Care. September 7, 2026 Beirut, 7 September 2026: The first Oncology Summit hosted by AstraZeneca in Lebanon under the theme "Leading the Future in Cancer Care" brought together leading oncology experts from Lebanon and Libya, alongside international faculty members, for two days of scientific exchange and collaboration focused on advancing cancer care and improving patient outcomes. The summit featured discussions on evolving standards of care, emerging scientific advances, and multidisciplinary approaches across lung cancer, gastrointestinal cancers, breast cancer, and ovarian cancer. "Scientific meetings such as this are essential to advancing oncology practice," said Dr. Arafat Tfayli, President of the Committee Responsible for Implementing Lebanon's National Cancer Control Plan. "They allow healthcare professionals to exchange experiences, discuss the latest evidence, and learn from regional and international experts. By strengthening collaboration and sharing knowledge, we can continue to elevate the quality of care available to patients across our region." "The challenges we face in cancer care are shared across many countries, and so too are the opportunities for progress," said Dr. Abdelmnam Elbarathi, Director of Tripoli Cancer Center, speaking on behalf of the Lybian delegation. "Bringing together experts from Libya and Lebanon creates meaningful opportunities for collaboration, learning, and professional exchange that can ultimately contribute to better care for patients. We look forward to strengthening these connections and continuing to work together to advance oncology practice throughout the region." The landmark event underscored AstraZeneca's commitment to supporting the oncology community through innovation, science, and partnerships, while reinforcing Lebanon's role as a regional platform for medical excellence and scientific dialogue. "Lebanon has long been recognized for its medical expertise, and we are proud to contribute to its role as a hub for scientific leadership and innovation," said Agnar Aboujaoude, Country Director, AstraZeneca Lebanon, who emphasized the power of collaboration in shaping the future of oncology care. "We are proud to bring together distinguished oncology experts from Lebanon, Libya, and the international scientific community around a shared purpose: improving the lives of patients with cancer. By fostering scientific exchange and regional collaboration, we can help accelerate the adoption of best practices, strengthen healthcare ecosystems, and ultimately bring new hope to patients and their families." The summit provided a platform for healthcare professionals to exchange knowledge, review emerging evidence, discuss real-world clinical experiences, and explore innovative approaches that are helping redefine cancer care worldwide. Throughout the discussions, participants examined the evolving oncology landscape and the opportunities to improve outcomes through earlier diagnosis, precision medicine, multidisciplinary care, and continued scientific advancement. "At AstraZeneca, our ambition is to eliminate cancer as a cause of death," said Mark Farid, Oncology Commercial Director for Near East & Maghreb at AstraZeneca, highlighting the company's long-term commitment to transforming cancer care through scientific innovation. "We continue to invest in one of the industry's broadest oncology portfolios and pipelines, advancing innovative science across multiple tumour types and treatment modalities. Through collaboration with healthcare professionals, researchers, and healthcare systems, we are working to transform outcomes and bring patients closer to a future where cancer can be detected earlier, treated more effectively, and, ultimately, cured." About AstraZeneca: AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca.